Advertisment
Indian Journal of Nephrology About us |  Subscription |  e-Alerts  | Feedback | Login   
  Print this page Email this page   Small font sizeDefault font sizeIncrease font size
 Home | Current Issue | Archives| Ahead of print | Search |Instructions |  Editorial Board  

Users Online:675

Official publication of the Indian Society of Nephrology
  Search
 
  
 ~  Similar in PUBMED
 ~  Search Pubmed for
 ~  Search in Google Scholar for
 ~  Article in PDF (250 KB)
 ~  Citation Manager
 ~  Access Statistics
 ~  Reader Comments
 ~  Email Alert *
 ~  Add to My List *
* Registration required (free)  

 
   References

 Article Access Statistics
    Viewed1041    
    Printed44    
    Emailed0    
    PDF Downloaded79    
    Comments [Add]    
    Cited by others 1    

Recommend this journal

 


 
  Table of Contents  
LETTER TO EDITOR
Year : 2012  |  Volume : 22  |  Issue : 2  |  Page : 155-156
 

C4d staining in allograft biopsies


1 Department of Pathology, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, Andhra Pradesh, India
2 Department of Nephrology, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, Andhra Pradesh, India

Date of Web Publication12-Jun-2012

Correspondence Address:
A K Prayaga
Department of Pathology, Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad 500 082, Andhra Pradesh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0971-4065.97155

Rights and Permissions



How to cite this article:
Kulkarni P, Uppin M S, Prayaga A K, Das U, Dakshinamurthy K V. C4d staining in allograft biopsies. Indian J Nephrol 2012;22:155-6

How to cite this URL:
Kulkarni P, Uppin M S, Prayaga A K, Das U, Dakshinamurthy K V. C4d staining in allograft biopsies. Indian J Nephrol [serial online] 2012 [cited 2019 Nov 18];22:155-6. Available from: http://www.indianjnephrol.org/text.asp?2012/22/2/155/97155


Sir,

Thank you for the comments on our article. The authors of the letter seem to have considered our C4d positivity synonymous with ABMR. The literature on C4d is still evolving and reflects controversies in terms of technique, biopsy policies, staining pattern, and utility. [1]

  1. The article contributes to expand the existing literature about C4d immunostaining with morphology of allograft biopsies in the setting of graft dysfunction. [2] As mentioned in our article, the absence of DSA was a drawback in recognizing the ABMR cases. The pattern of C4d staining in acute rejection is "focal" rather than "diffuse." The significance of such positivity has been mentioned as "controversial" in the absence of the sufficient published literature as mentioned in the discussion of our article. [2] To quote Banff 2007 publication "the prognosis of focal positive cases is intermediate between the diffuse and negative ones. Significance of these cases is not well established in the absence of consensus criteria and detection of antibody with the long-term outcome will only resolve the issue." [3],[4] Banff 2003 mentions that the presence of C4d with changes of chronicity should be taken as chronic humoral rejection and helps to distinguish immune and nonimmune type of chronicity. [5] So the presence of diffuse C4d staining with features of IFTA was suggestive of a humoral component. The percentage positivity in cases of CAN is comparable to that mentioned in the literature; one of these studies is an Indian study that was the only published study from the country at the time of our publication. [6],[7]
  2. Ranjan et al. mentioned that C4d positivity has no correlation with follow up serum creatinine levels. It has been mentioned that C4d positive grafts have lower survival as compared to negative ones; however, that does not correlate with serum creatinine levels. [7] Volker et al. discussed the differences in management strategies between C4d positive cases with normal and increased creatinine. [8] Hence, low serum creatinine levels in our study need not be used as an indicator to suspect the accuracy of C4d results.
  3. The standard immunosuppression protocol at our centre includes cyclosporine/tacrolimus with MMF and steroids. The study was retrospective and C4d results were not available at the time of treatment. The clinical details including HLA match and crossmatch were not given as it was beyond the scope of the paper. The prospective data including clinical details, treatment, and management issues will be discussed in detail in our forthcoming article.
  4. Immunohistochemistry was validated by Troxell et al. who found it "a reliable tool to indicate the presence of C4d and the results of IF and IHC are very much comparable." [6] To quote the updates of Banff 2007 classification "the C4d scoring is based on percentage of stained tissue on IF/IHC ……….." It does not mention IF alone as current standard of care testing. Hence, the argument that the technique is not standardized is not valid. [4] We also want to bring attention to a recent article published by Haas (2011) about C4d negative AMR wherein morphologically proven AHR is negative by IF also and still deserves to be treated as AHR. [9]
  5. We accept the mistakes in numbers in the abstract and main text. However, it has not influenced the statistical analysis and the results.


Finally we are happy to know that the incidence of ABMR is low in the author's center. But we have about 11% cases designated as ABMR in our center (unpublished data). We have seen similar percentages from other centers in India as per the published literature. [7],[10]

 
  References Top

1.Cohen D, Colvin RB, Daha MR, Drachenberg CB, Haas M, Nickeleit V, et al. Pros and cons for C4d as a biomarker. Kidney Int 2012;81:628-39.  Back to cited text no. 1
[PUBMED]  [FULLTEXT]  
2.Kulkarni P, Uppin MS, Prayaga AK, Das U, Dakshina Murthy KV. Renal allograft pathology with C4d immunostaining in patients with graft dysfunction. Indian J Neprol 2011;21:239-44.  Back to cited text no. 2
    
3.Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008;8:753-60.  Back to cited text no. 3
[PUBMED]  [FULLTEXT]  
4.Colvin RB. Antibody- mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol 2007;18:1046-56.  Back to cited text no. 4
[PUBMED]  [FULLTEXT]  
5.Racusen LC, Colvin RB, Solez K, Mihatsch MJ, Halloran PF, Campbell PM, et al. Antibody-mediated rejection criteria- an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003;3:708-14.  Back to cited text no. 5
[PUBMED]  [FULLTEXT]  
6.Troxell ML, Weintraub LA, Higgins JP, Kambham N. Comparison of C4d immunostaining methods in renal allograft biopsies. Clin J Am Soc Nephrol 2006;1:583-91.  Back to cited text no. 6
[PUBMED]  [FULLTEXT]  
7.Ranjan P, Nada R, Jha V, Sakhuja V, Joshi K. The role of C4d immunostaining in the evaluation of causes of renal allograft dysfunction. Nephrol Dial Transplant 2008;23:1735-41.  Back to cited text no. 7
[PUBMED]  [FULLTEXT]  
8.Nickeleit V, Mihatsch MJ. Kidney transplants, antibodies and rejection: is C4d a magic marker? Nephrol Dial Transplant 2003;18:2232-9.  Back to cited text no. 8
[PUBMED]  [FULLTEXT]  
9.Haas M. C4d-negative antibody-mediated rejection in renal allografts: evidence for its existence and effect on graft survival. Clin Nephrol 2011;75:271-8.  Back to cited text no. 9
[PUBMED]  [FULLTEXT]  
10.Kanodia KV, Vanikar AV, Trivedi HL. Study of acute antibody mediated rejection in renal allograft biopsies. Transplant Proc 2008;40:1099-103.  Back to cited text no. 10
[PUBMED]  [FULLTEXT]  



This article has been cited by
1 Capillary Dilation and Rarefaction Are Correlated with Intracapillary Inflammation in Antibody-Mediated Rejection
Xue Li,Qiquan Sun,Mingchao Zhang,Kenan Xie,Jinsong Chen,Zhihong Liu
Journal of Immunology Research. 2014; 2014: 1
[Pubmed] | [DOI]



 

Top
Print this article  Email this article
 

    

Indian Journal of Nephrology
Published by Wolters Kluwer - Medknow
Online since 20th Sept '07